Stochastic modelling of tumorigenesis in p53 deficient mice

被引:0
|
作者
JH Mao
KA Lindsay
A Balmain
TE Wheldon
机构
[1] University of Glasgow,Department of Radiation Oncology
[2] CRC Beatson Laboratories,undefined
来源
British Journal of Cancer | 1998年 / 77卷
关键词
D O I
暂无
中图分类号
学科分类号
摘要
Stochastic models of tumorigenesis have been developed to investigate the implications of experimental data on tumour induction in wild-type and p53-deficient mice for tumorigenesis mechanisms. Conventional multistage models in which inactivation of each p53 allele represents a distinct stage predict excessively large numbers of tumours in p53-deficient genotypes, allowing this category of model to be rejected. Multistage multipath models, in which a p53-mediated pathway co-exists with one or more p53-independent pathways, are consistent with the data, although these models require unknown pathways and do not enable age-specific curves of tumour appearance to be computed. An alternative model that fits the data is the 'multigate' model in which tumorigenesis results from a small number of gate-pass (enabling) events independently of p53 status. The role of p53 inactivation is as a rate modifier that accelerates the gate-pass events. This model implies that wild-type p53 acts as a 'caretaker' to maintain genetic uniformity in cell populations, and that p53 inactivation increases the probability of occurrence of a viable cellular mutant by a factor of about ten. The multigate model predicts a relationship between the time pattern of tumour occurrence and tumour genotype that should be experimentally testable. Stochastic modelling may help to distinguish 'gatekeeper' and 'caretaker' genes in other tumorigenic pathays.
引用
收藏
页码:243 / 252
页数:9
相关论文
共 50 条
  • [41] Impact of ionizing radiation and genetic background on mammary tumorigenesis in p53-deficient mice
    Backlund, MG
    Trasti, SL
    Backlund, DC
    Cressman, VL
    Godfrey, V
    Koller, BH
    [J]. CANCER RESEARCH, 2001, 61 (17) : 6577 - 6582
  • [42] A TERATOLOGIC SUPPRESSOR ROLE FOR P53 IN BENZO[A]PYRENE-TREATED TRANSGENIC P53-DEFICIENT MICE
    NICOL, CJ
    HARRISON, ML
    LAPOSA, RR
    GIMELSHTEIN, IL
    WELLS, PG
    [J]. NATURE GENETICS, 1995, 10 (02) : 181 - 187
  • [43] Role of T antigen interactions with p53 in tumorigenesis
    Pipas, JM
    Levine, AJ
    [J]. SEMINARS IN CANCER BIOLOGY, 2001, 11 (01) : 23 - 30
  • [44] Mutations in the p53 and SCID genes cooperate in tumorigenesis
    Nacht, M
    Strasser, A
    Chan, YR
    Harris, AW
    Schlissel, M
    Bronson, R
    Jacks, T
    [J]. GENES & DEVELOPMENT, 1996, 10 (16) : 2055 - 2066
  • [45] TIMING OF P53 MUTATIONS DURING ASTROCYTOMA TUMORIGENESIS
    DELARCO, A
    GARCIA, J
    ARRIBAS, C
    BARRIO, R
    BLAZQUEZ, MG
    IZQUIERDO, JM
    IZQUIERDO, M
    [J]. HUMAN MOLECULAR GENETICS, 1993, 2 (10) : 1687 - 1690
  • [46] Post-translational modification of p53 in tumorigenesis
    Ann M. Bode
    Zigang Dong
    [J]. Nature Reviews Cancer, 2004, 4 : 793 - 805
  • [47] Effects of p53 knockout on ochratoxin A-induced genotoxicity in p53-deficient gpt delta mice
    Hibi, Daisuke
    Kijima, Aki
    Suzuki, Yuta
    Ishii, Yuji
    Jin, Meilan
    Sugita-Konishi, Yoshiko
    Yanai, Tokuma
    Nishikawa, Akiyoshi
    Umemura, Takashi
    [J]. TOXICOLOGY, 2013, 304 : 92 - 99
  • [48] Post-translational modification of p53 in tumorigenesis
    Bode, AM
    Dong, ZG
    [J]. NATURE REVIEWS CANCER, 2004, 4 (10) : 793 - 805
  • [49] Role of p53 circuitry in tumorigenesis: A brief review
    Niazi, Sarfaraj
    Purohit, Madhusudan
    Niazi, Javed H.
    [J]. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2018, 158 : 7 - 24
  • [50] In vivo analysis of mammary and non-mammary tumorigenesis in MMTV-cyclin D1 transgenic mice deficient in p53
    Yoshitaka Hosokawa
    Alexandros Papanikolaou
    Robert D. Cardiff
    Katsuhiko Yoshimoto
    Megan Bernstein
    Timothy C. Wang
    Emmett V. Schmidt
    Andrew Arnold
    [J]. Transgenic Research, 2001, 10 : 471 - 478